Vertex Pharmaceuticals

Vertex Pharmaceuticals (VRTX) is currently trading at $438.71. The stock has a 52-week range of $366.54 to $509.50 and a market capitalization of $111.45B.

Vertex Pharmaceuticals has a P/E ratio of 28.7 (forward P/E: 20.0), a dividend yield of none, and 1-year performance of -9.4%. 2 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.

There have been 81 insider transactions for VRTX in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.

Vertex Pharmaceuticals (VRTX) has returned -9.4% over the past 12 months. The stock traded between $366.54 and $509.50 during this period, and is currently at $438.71.

2 tracked hedge funds currently hold VRTX in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.

Vertex Pharmaceuticals (VRTX) has a market capitalization of $111.45B. The trailing P/E ratio is 28.7 and forward P/E is 20.0. The stock is classified in the Healthcare sector.

Vertex Pharmaceuticals reported revenue of $12.00B with net income of $3.95B and a profit margin of 0.33%. The stock has a beta of 0.37.

Vertex Pharmaceuticals (VRTX) operates in the Healthcare sector. It is held by 2 tracked hedge funds. See the ownership table above for the complete list.